跳至主要内容
临床试验/NCT00406744
NCT00406744终止3 期

Evaluation of Efficacy of Intravitreal Bevacizumab Retreatments

Asociación para Evitar la Ceguera en México2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2006年5月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
终止
发起方
入组人数
20
试验地点
2
主要终点
Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram

研究概览

简要总结

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
60 Years 至 95 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • * Any visual acuity
  • OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.
  • Active angiogram leakage

排除标准

  • * Basal Inflammatory disease
  • Endoftalmitis history
  • Lesions bigger than 5400 u or with scarring greater than 50% of lesion.

结局指标

主要结局

Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram

次要结局

未报告次要终点

研究者

发起方
Asociación para Evitar la Ceguera en México
申办方类型
Other

研究点 (2)

Loading locations...

相似试验